Did Neurocept face advisory committee reviews, clinical holds, or delays during its approval process?

1. What the coverage says: Neurocept appears in consumer supplement reporting, not FDA approval lists

The items returned by the current search are largely consumer-facing reviews and advertorials describing Neurocept as a brain‑health supplement and discussing ingredients, user impressions, and purchasing advice ^{[1] [3] [4]}. These pieces frame Neurocept as a wellness product rather than an FDA‑regulated prescription drug, and one Trustpilot reviewer explicitly states “Neurocept is not an FDA‑approved medication” while calling the product a potential scam ^[2].

2. No sourced evidence of an FDA new‑drug application or review process

Authoritative compilations of FDA novel drug approvals and trackers are included in the search results (for example, the FDA’s Novel Drug Approvals page and Drugs.com’s new approvals list), yet none of the provided extracts or links mention Neurocept as a novel drug subject to an NDA/BLA review, suggesting Neurocept is not listed among FDA drug approvals in these sources ^{[5] [6]}. Therefore, the current reporting does not support the premise that Neurocept underwent the FDA drug‑approval pathway subject to advisory committees or clinical holds (available sources do not mention Neurocept in FDA approval lists).

3. Customer complaints and skepticism are prominent in available reporting

Several consumer complaint pages and review aggregators in the search results assert doubts about Neurocept’s claims and regulatory status, including accusations that marketing materials falsely claim FDA approval and that ingredients differ from those advertised ^{[2] [7]}. These are consumer‑level allegations and do not equate to evidence of formal regulatory action such as an FDA clinical hold or advisory committee review ^[2].

4. What would indicate advisory‑committee review or clinical hold — and why those signals are absent here

Advisory‑committee reviews, clinical holds, and PDUFA target‑date delays are typically documented in regulatory‑oriented outlets and FDA action summaries cited in the search results (examples include NeurologyLive and other specialty news pieces that list accepted NDAs, PDUFA dates, and instances where the FDA extended review after information requests) ^{[8] [9]}. The absence of Neurocept from those regulatory calendars and FDA novel‑approval lists in the provided materials indicates the reporting available to us does not treat Neurocept as a product that entered that formal drug‑approval pipeline ^{[5] [9]}.

5. Alternative interpretation: supplement vs. drug — different regulatory tracks

If Neurocept is marketed as a dietary supplement rather than a prescription drug, it would not go through the FDA’s NDA/BLA process, advisory panels, or clinical holds the way a novel therapeutic would. The consumer‑oriented reviews and advertorials emphasize the product’s role in “brain health” and general wellness rather than treatment of disease, which aligns with how many supplements are presented in media coverage ^{[1] [4]}. Current sources do not explicitly label Neurocept as a drug or show an application to the FDA for approval (available sources do not mention a regulatory classification decision for Neurocept).

6. Limits of available reporting and next steps for verification

The search results are heavily weighted to promotional reviews and consumer complaints; they do not include a regulatory filing or FDA communication naming Neurocept. To confirm definitively whether Neurocept was ever the subject of an advisory committee review, clinical hold, or approval delay, one would need to search the FDA’s database of drug approvals, advisory committee calendars, clinical hold notices, or official company press releases and SEC filings—documents not present in the provided sources (available sources do not include FDA or company regulatory filings for Neurocept).

Summary conclusion: Based on the materials you supplied, Neurocept is covered as a consumer brain‑support supplement with complaints about fraudulent claims and lack of FDA approval status in customer reviews, and the provided regulatory trackers and FDA lists do not show Neurocept undergoing advisory‑committee reviews, clinical holds, or formal approval delays ^{[2] [1] [5] [6]}.